To investigate whether the expression of MRGPRX2 and CLM-1 in serum of patients with allergic rhinitis has a new basis for judging patients with allergic rhinitis.

Study on the effect and mechanism of flavonoids in Sophora japonica Thunb in the treatment of allergic rhinitis

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400083665

Enrollment

Unknown

Registered

2024-04-30

Start date

2024-05-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Allergic rhinitis patient group:None

Healthy control group:None

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 12 and above; 2. It is diagnosed as allergic rhinitis through typical clinical symptoms (recurrent sneezing, runny nose, stuffy nose or itchy nose) and signs, and the symptoms have obvious seasonality; 3. Allergen test results meet the following standards: Weed pollen serum sIgE = II or skin test = "++"; Dust mites, mold and pet serum sIgE detection level 0 or skin test results "-".

Exclusion criteria

Exclusion criteria: 1. Patients with malignant tumors; 2. Pregnant or lactating; 3. Other serious liver, kidney, heart, hematopoiesis, nervous system or mental illness; 4. Other circumstances that the researcher thinks are not suitable for selection.

Design outcomes

Primary

Measure	Time frame
MRGPRX2;CLM-1;	—

Secondary

Measure	Time frame
IL-4;IL-5;IL-13;TNF-ß;IFN-?;	—

Countries

China

Contacts

Public ContactXue Wenjing

Yan 'an Traditional Chinese Medicine Hospital

263314240@qq.com+86 188 9110 3436

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026